Abstract 230P
Background
As far as we know, we have yet to establish the long-term cancer outcomes of partial cystectomy (PC) for urothelial carcinoma. Radical cystectomy (RC) is a complex and risky procedure for muscle invasive bladder cancer (MIBC). In some cases, PC with bilateral pelvic lymph node dissection can be an option in selected patients but may compromise oncologic success. We compared the recurrence patterns and survival rates of patients who had either partial or radical cystectomy for MIBC patients with solitary tumor.
Methods
We identified 30 solitary MIBC patients with downgraded staging below cT2 after TURBT or neoadjuvant systemic therapy at our hospital from 2014 to 2021. They had either partial cystectomy or radical cystectomy and all of them had pathological T staging below pT2. We compare the overall survival, cancer specific survival and recurrence pattern including local recurrence and metastasis.
Results
The median postoperative follow-up period was 5 years, with a range of 1 to 8.5 years. When comparing patients who underwent partial cystectomy to those who underwent radical cystectomy, no significant differences were observed in the 5-year distant recurrence-free survival rates (100% vs 94.5%, p = 0.23) or cancer-specific survival rates (91.7% vs 100%, p = 0.43). Furthermore, there were no instances of extravesical pelvic tumor recurrence in either the partial or radical cystectomy groups postoperatively. Among the patients who underwent partial cystectomy, 6 out of 12 (50%) experienced intravesical recurrence of the tumor, and only 1 out of 12 (5.5%) ultimately required conversion to radical cystectomy.
Conclusions
For patients with solitary muscle-invasive bladder cancer that has been downgraded to a stage below cT2, partial cystectomy is a feasible option as it offers a similar metastasis-free survival and cancer-specific survival rate when compared to radical cystectomy. However, it is crucial to acknowledge that patients who received partial cystectomy remain at risk of experiencing recurrence within the bladder. Therefore, it is imperative to provide these patients with appropriate counseling and ongoing monitoring to address this potential risk.
Clinical trial identification
Not applicable
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract